NEW YORK (GenomeWeb) – AstraZeneca today announced a collaboration with Roche to develop a companion diagnostic for AstaZeneca's investigational compound for non-small cell lung cancer.

The test will be directed at AZD9291 and will be developed to identify epidermal growth factor receptor mutations in tumor tissue as well as plasma samples from patients with NSCLC. It also will be designed to optimize the clinical development of AZD9291 for patients who are resistant to first-generation EGFR tyrosine kinase inhibitors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

With a new collection, PLOS highlights negative results it has published.